Nonresponse and Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Treatment

被引：9

作者：

Chuluunbat, Tsengelmaa ^{[1
]}

Chan, R. V. Paul ^{[2
]}

Wang, Nan-Kai ^{[3
,4
]}

Lien, Reyin ^{[4
,5
]}

Chen, Yen-Po ^{[3
,4
]}

Chao, An-Ning ^{[3
,4
]}

Chen, Kuan-Jen ^{[3
,4
]}

Chen, Tun-Lu ^{[3
,4
]}

Hwang, Yih-Shiou ^{[3
,4
]}

Lai, Chi-Chun ^{[3
,4
]}

Wu, Wei-Chi ^{[3
,4
]}

机构：

[1] Natl Ctr Maternal & Child Hlth, Dept Ophthalmol, Ulaanbaatar, Mongolia

[2] Univ Illinois, Dept Ophthalmol & Visual Sci, Illinois Eye & Ear Infirm, Chicago, IL USA

[3] Chang Gung Mem Hosp, Dept Ophthalmol, Taoyuan 333, Taiwan

[4] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[5] Chang Gung Mem Hosp, Dept Pediat, Taoyuan, Taiwan

来源：

OPHTHALMIC SURGERY LASERS & IMAGING RETINA | 2016年 / 47卷 / 12期

关键词：

ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB MONOTHERAPY; LASER TREATMENT; PRETHRESHOLD; CRYOTHERAPY; THRESHOLD; INJECTION; THERAPY;

D O I：

10.3928/23258160-20161130-03

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

BACKGROUND AND OBJECTIVE: To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment. PATIENTS AND METHODS: This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included. RESULTS: Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 LogMAR (range: 0 LogMAR to 0.8 LogMAR) with a mean follow-up of 25.2 months +/- 6.8 months. CONCLUSIONS: IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment.

引用

页码：1095 / 1105

页数：11

共 34 条

[1] Pharmacokinetics of intravitreal ranibizumab (Lucentis) [J].

Bakri, Sophie J. ;

Snyder, Melissa R. ;

Reid, Joel M. ;

Pulido, Jose S. ;

Ezzat, Mohamed K. ;

Singh, Ravinder J. .

OPHTHALMOLOGY, 2007, 114 (12) :2179-2182

[2] Primary Intravitreal Ranibizumab for High-Risk Retinopathy of Prematurity [J].

Baumal, Caroline R. ;

Goldberg, Roger A. ;

Fein, Jordana G. .

OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (04) :432-438

[3] Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration [J].

Bressler, Susan B. .

OPHTHALMOLOGY, 2009, 116 (10) :S1-S7

[4] INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY Comparison Between Ranibizumab and Bevacizumab [J].

Chen, San-Ni ;

Lian, Iebin ;

Hwang, Ya-Chi ;

Chen, Yi-Hsing ;

Chang, Yao-Chung ;

Lee, Kun-Hsien ;

Chuang, Chih-Chun ;

Wu, Wei-Chi .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (04) :667-674

[5] A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years - Part 2. Refractive outcome [J].

Connolly, BP ;

Ng, EYJ ;

McNamara, JA ;

Regillo, CD ;

Vander, JF ;

Tasman, W .

OPHTHALMOLOGY, 2002, 109 (05) :936-941

[6] Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies [J].

Csaky, Karl ;

Do, Diana V. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (05) :647-656

[7] Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment A Randomized Clinical Trial [J].

Geloneck, Megan M. ;

Chuang, Alice Z. ;

Clark, W. Lloyd ;

Hunt, Michael G. ;

Norman, Alan A. ;

Packwood, Eric A. ;

Tawansy, Khaled A. ;

Mintz-Hittner, Helen A. .

JAMA OPHTHALMOLOGY, 2014, 132 (11) :1327-1333

[8]

Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684

[9] Managing patients treated with bevacizumab combination therapy [J].

Gordon, MS ;

Cunningham, D .

ONCOLOGY, 2005, 69 :25-33

[10] Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity [J].

Hoerster, Robert ;

Muether, Philipp ;

Dahlke, Claudia ;

Mehler, Katrin ;

Oberthuer, Andre ;

Kirchhof, Bernd ;

Fauser, Sascha .

ACTA OPHTHALMOLOGICA, 2013, 91 (01) :e74-e75

← 1 2 3 4 →